World's Best Scientists 2026 revealed!
Mary-Ellen Taplin

Mary-Ellen Taplin

Overview

Mary-Ellen Taplin is affiliated with Harvard University in the United States and specializes in research spanning medicine and biochemistry, genetics, and molecular biology. Their work predominantly focuses on prostate cancer treatment and research, covering aspects such as diagnosis, treatment, cancer genomics and diagnostics, as well as cancer metabolism and genetics.

Their main research topics include:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • Bladder and Urothelial Cancer Treatments
  • Estrogen and related hormone effects

Mary-Ellen Taplin's research is categorized within the subfields of pulmonary and respiratory medicine, cancer research, genetics, surgery, and oncology.

Frequent publication venues for this researcher include:

  • Journal of Clinical Oncology
  • European Urology
  • Cancer Cell
  • JCO Oncology Practice
  • Clinical Cancer Research

Some of the recent papers authored or coauthored by Mary-Ellen Taplin are:

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019, 2020, Journal of Clinical Oncology
  • Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer, 2020, Cancer Cell
  • Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update, 2021, Journal of Clinical Oncology
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer, 2020, Journal of Clinical Oncology

Collaborations are a significant aspect of their work, with frequent co-authors including Himisha Beltran, Alicia K. Morgans, Martin Gleave, Susan Halabi, and Charles J. Ryan.

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

    Mary-Ellen Taplin;Glenn J. Bubley;Todd D. Shuster;Martha E. Frantz

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

    Howard I Scher;Tomasz M Beer;Celestia S Higano;Aseem Anand

  • Genomic correlates of clinical outcome in advanced prostate cancer.

    Wassim Abida;Joanna Cyrta;Joanna Cyrta;Glenn Heller;Davide Prandi

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options

    Martin G. Sanda;Jeffrey A. Cadeddu;Erin Kirkby;Ronald C. Chen

  • Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

    Viktor A. Adalsteinsson;Viktor A. Adalsteinsson;Gavin Ha;Gavin Ha;Samuel S. Freeman;Samuel S. Freeman;Atish D. Choudhury

  • Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist

    Mary-Ellen Taplin;Glenn J. Bubley;Yoo-Joung Ko;Eric J. Small

  • The long tail of oncogenic drivers in prostate cancer

    Joshua Armenia;Stephanie A. M. Wankowicz;Stephanie A. M. Wankowicz;David Liu;David Liu;Jianjiong Gao

  • Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

    D. Andrew Loblaw;Katherine S. Virgo;Robert Nam;Mark R. Somerfield

  • Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

    Jens G. Lohr;Jens G. Lohr;Viktor A. Adalsteinsson;Viktor A. Adalsteinsson;Kristian Cibulskis;Atish D. Choudhury;Atish D. Choudhury

  • Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

    Mary-Ellen Taplin;Steven P. Balk

  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663

    Mary-Ellen Taplin;Barur Rajeshkumar;Susan Halabi;Cary P. Werner

  • Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

    Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan

Frequent Co-Authors

Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Eliezer M. Van Allen
Eliezer M. Van Allen Harvard University
Steven P. Balk
Steven P. Balk Beth Israel Deaconess Medical Center
Peter S. Nelson
Peter S. Nelson Fred Hutchinson Cancer Research Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Christopher Sweeney
Christopher Sweeney Harvard University
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Eric J. Small
Eric J. Small University of California, San Francisco
William Oh
William Oh Icahn School of Medicine at Mount Sinai
Toni K. Choueiri
Toni K. Choueiri Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA goes beyond becoming a traditional physician. There are numerous flexible, accredited online programs for those interested in healthcare careers. For nurses aiming to move into advanced practice or leadership roles, the best online bsn to dnp programs offer comprehensive training with the convenience of remote learning.

Pharmacy is another area seeing strong online options. Aspiring pharmacists can find reputable online pharmacy programs that prepare them for licensure and clinical practice—perfect for those needing to balance study with other commitments.

For students interested in the administrative side of medicine, consider a health information management degree online. These programs train professionals to securely organize, analyze, and manage patient data, a vital part of modern healthcare systems.

Finally, if you prefer shorter programs or entry-level roles, medical billing and coding online courses cost less time and money to complete. They allow you to quickly gain skills for in-demand jobs supporting hospitals and clinics across the country.

Best Scientists Citing Mary-Ellen Taplin

Trending Scientists

Recently Published Articles